Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
NCT00301509
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
NCT02333292
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
NCT01482767
Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
NCT01447394
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
NCT01195181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nevirapine
Nevirapine
nevirapine: 400 mg a day.
efavirenz, protease inhibitors
efavirenz: 600 mg a day
Non-nevirapine
Nevirapine
nevirapine: 400 mg a day.
efavirenz, protease inhibitors
efavirenz: 600 mg a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nevirapine
nevirapine: 400 mg a day.
efavirenz, protease inhibitors
efavirenz: 600 mg a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Older than 18 years.
* Chronic hepatitis C.
* Undetectable HIV viral load during one year before starting study.
* To have not received HCV therapy during one year before starting study.
* To have not started efavirenz or protease inhibitors o nucleoside analogs during 6 months before starting study.
* Non contraindications for drugs included in this study.
* To change an antiretroviral regimen including efavirenz or protease inhibitors by nevirapine due to side effects, interactions or pregnancy (NVP group)
* To continue with a antiretroviral regimen including efavirenz or protease inhibitors (non-NVP group)
Both groups will be matched according to these variables:
* Liver stiffness.
* HCV genotype.
* Hospital.
* Time from starting antiretroviral therapy.
* Previous third drug (EFV or PI) to introduction of NVP.
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Valme University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
INFECTIOUS DISEASES UNIT, VALME UNIVERSITY HOSPITAL, SEVILLE, SPAIN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Valme University Hospital
Seville, Seville, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JAP-NEV-2010-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.